Abstract
Employing a multicolour flow cytometry assay, 133 B-chronic lymphocytic leukaemia (B-CLL) cases were analysed for surface expression of CD38. Based on a cut-off value of 20%, CLL patients were categorised into a CD38-positive (⩾20%, n = 56) and a CD38-negative subgroup (<20%, n = 77) and separately analysed for clinical and laboratory parameters. Patients in the CD38-positive cohort were characterised by an unfavourable clinical course with a more advanced disease stage, poor responsiveness to chemotherapy, short time to initiation of first treatment and shorter survival. In contrast, the CD38- negative group required minimal or no treatment, remained treatment-free for a longer time period and had prolonged survival (P < 0.05). CD38 expression was a robust marker in the majority of patients in that it was stable over time and not significantly influenced by chemotherapy. In conclusion, our data confirm recent studies suggesting a role of CD38 as a predictor of clinical outcome in patients with B-CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.leu.2402339/MediaObjects/41375_2002_Article_BF2402339_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.leu.2402339/MediaObjects/41375_2002_Article_BF2402339_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.leu.2402339/MediaObjects/41375_2002_Article_BF2402339_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.leu.2402339/MediaObjects/41375_2002_Article_BF2402339_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.leu.2402339/MediaObjects/41375_2002_Article_BF2402339_Fig5_HTML.gif)
Similar content being viewed by others
References
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS . Clinical staging of chronic lymphocytic leukemia Blood 1975 46: 219–234
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F . A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 1981 48: 198–206
Rai KR . Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment Haematologica 1999 84: 94–95
Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia New Engl J Med 2000 343: 1750–1757
Zwiebel JA, Cheson BD . Chronic lymphocytic leukemia: staging and prognostic factors Semin Oncol 1998 25: 42–59
Binet JL . Prognostic factors in chronic lymphocytic leukaemia Haematologica 1999 84: 96–97
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 1999 94: 1840–1847
Hamblin T, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 1999 94: 1848–1854
Hamblin T, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK . Immunoglobulin V genes and CD38 expression in CLL Blood 2000 95: 2455–2457
Thunberg U, Johnson A, Roos G, Thorn I, Tobin G, Sallstrom J, Sundstrom C, Rosenquist R . CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia Blood 2001 97: 1892–1894
Deaglio S, Mehta K, Malavasi F . Human CD38: a (r)evolutionary story of enzymes and receptors Leuk Res 2001 25: 1–12
Kumagai M, Coustan-Smith E, Murray DJ, Silvennoinen O, Murti KG, Evans WE, Malavasi F, Campana D . Ligation of CD38 suppresses human B lymphopoiesis J Exp Med 1995 181: 1101–1110
Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U, Mehta K, Malavasi F . CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes Chem Immunol 2000 75: 99–120
Höffkes HG, Schmidtke G, Uppenkamp M, Schmücker U . Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry Clin Diagn Lab Immunol 1996 3: 30–36
Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, van't Veer MB . The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL) Blood 1998 92: 596–599
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB . Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL) Leukemia 1995 9: 1783–1786
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Döhner K, Bentz M, Lichter P . Genomic aberrations and survival in chronic lymphocytic leukemia New Engl J Med 2001 343: 1910–1916
Matrai Z, Lin K, Dennis M, Sherrington P, Zuzel M, Pettitt AR, Cawley JC . CD38 expression and Ig VH gene mutation in B cell chronic lymphocytic leukemia Blood 2001 97: 1902–1903
Acknowledgements
This work represents a part of MNs MD thesis. We are indebted to numerous colleagues for generously contributing information on the clinical course and treatment histories of the study patients.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dürig, J., Naschar, M., Schmücker, U. et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16, 30–35 (2002). https://doi.org/10.1038/sj.leu.2402339
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402339
Keywords
This article is cited by
-
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
Journal of Hematology & Oncology (2020)
-
Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?
Indian Journal of Hematology and Blood Transfusion (2020)
-
Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia
BMC Research Notes (2018)
-
Prognostic Factors in the Era of Targeted Therapies in CLL
Current Hematologic Malignancy Reports (2018)
-
Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients
Indian Journal of Hematology and Blood Transfusion (2017)